the board’s acting chair, was also revealing. She wrote, as translated from French, that there is a “dialogue of the deaf that has been going on for years between the pharmaceutical industry and the PMPRB, which has resulted in costly legal proceedings for Canadians that could have been avoided.” Her ideas to re-examine pricing policy and methods and her “concerns about the legality of part of the reform” were ignored by the board.
The PMPRB has outlived its usefulness and should be disbanded. If it is to remain, the federal government must clean it out. In February, Thomas Digby, an intellectual-property lawyer with more than 25 years of experience working with the pharmaceutical sector, was appointed as the board’s new chair. This may be a step in the right direction, but that remains to be seen.
Everyone would like drugs to be cheaper, but not at the expense of having pharmaceutical companies and their innovative medicines bypass Canada. Several adversarial barriers to launching novel medicines already exist in this country, and Canadians don’t need additional anti-industry zealotry from their own federal agencies to deter developers. Without aFollow
Business Business Latest News, Business Business Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: KitcoNewsNOW - 🏆 13. / 78 Read more »
Source: globeandmail - 🏆 5. / 92 Read more »